TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05765110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic OFF drug state
Description: Experiment will be performed without dopaminergic medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic OFF drug state
Description: Experiment will be performed without dopaminergic medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS OFF state
Description: Turning off the stimulation during experiment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic ON drug state
Description: Experiment will be performed with dopaminergic medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic ON drug state
Description: Experiment will be performed with dopaminergic medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS ON state
Description: Experiment will be performed with stimulation (ON condition)
Study: NCT06214026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: META-Arc foot locked
Description: Participants are provided with the META-Arc from WIllowWood Global, and a locking mechanism prevents side-to-side motion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: META-Arc foot unlocked
Description: Participants are provided with the META-Arc from WIllowWood Global allowing side-to-side motion.
Study: NCT06646068

Intervention type: OTHER
Group type: OTHER
Intervention: Philips 66 with CBL
Description: Each team is given six minutes to brainstorm ideas or solutions to specific clinical cases. This technique is applied during case-based learning sessions to enhance clinical judgment and critical thinking skills among nursing students.
Study: NCT04888650

Intervention type: OTHER
Intervention: questionnaire
Description: electronic questionnaire
Study: NCT04829695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine drug combination
Description: Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
Study: NCT06577428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: administered SC
Study: NCT06537362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthpiece with cheek-holder
Description: A cheek support integrated into the mouthpiece is used for the measures
Study: NCT05320861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]SJP-0008
Description: Single oral dose of \[14C\]SJP-0008
Study: NCT05271799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be administered
Study: NCT06453304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leddermix
Description: Intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycirrhizin
Description: Intracanal medication
Study: NCT05635708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered Orally
Study: NCT06181708

Intervention type: OTHER
Intervention: N/A - Questionnaire based study
Description: Questionnaire based study

Intervention type: OTHER
Intervention: N/A - Questionnaire based study
Description: Questionnaire based study
Study: NCT06578663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: including transcutaneous electrical nerve stimulation (TENS) and an exercise therapy program (stretching exercises, both hip and knee strengthening, balance, and stability exercise)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional physical therapy
Description: including transcutaneous electrical nerve stimulation (TENS) and an exercise therapy program (stretching exercises, both hip and knee strengthening, balance, and stability exercise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: including transcutaneous electrical nerve stimulation (TENS) and an exercise therapy program (stretching exercises, both hip and knee strengthening, balance, and stability exercise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Dry Needling
Description: In electrical dry needling, needle electrodes are used to deliver an electric current to the taut muscle band or the pain-generating trigger point. Low-frequency currents are thought to improve the physiological effects of the therapy by using electrical stimulation to enhance certain physiological reactions and achieve a speedier analgesic and anesthetic effect than that obtained with standard dry needling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate iontophoresis
Description: Galvanic current mode will be used to deliver the cream through the skin. One gram of GS will be placed on positive electrode (being positively charged using Trans-arthral electrode placement technique) for administration of Iontophoresis \[40mA-min (2mA x 20minutes)\].
Study: NCT04709419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celliant Diabetic Medical Socks
Description: Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control (placebo) Medical Socks
Description: The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
Study: NCT05987449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXT007
Description: Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
Study: NCT05146674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group).
Study: NCT06209710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Pulmonary Angioplasty combined with Pulmonary Artery Denervation
Description: Participants in the intervention arm will undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN), as part of this phase 2/3 clinical trial. The trial aims to determine the optimal number of radiofrequency (RF) ablation points required for effective PADN based on pulmonary artery size or diameter. The BPA procedure addresses segmental and subsegmental thrombi masses through pulmonary artery dilation, while the PADN procedure involves the placement of a denervation catheter near the bifurcation of the main pulmonary artery. RF energy is selectively applied, and ablation points are determined based on individual patient characteristics and expected therapeutic effects. This unique approach seeks to customize the intervention to the patient's specific pulmonary anatomy, contributing to the overall effectiveness of the treatment strategy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Balloon Pulmonary Angioplasty with Sham Pulmonary Artery Denervation
Description: Participants receive Balloon Pulmonary Angioplasty (BPA) combined with a sham Pulmonary Artery Denervation (PADN) procedure. The sham PADN involves catheter placement mimicking the actual procedure without the application of radiofrequency energy
Study: NCT05608629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Non-Invasive Vagus Nerve Stimulation
Description: The parasym is a system for delivering a fixed signal to stimulate the auricular branch of the vagus nerve. The device used is available without prescription in UK and EU. Similar devices have been used to treat migraine and one is in testing to be used for atrial fibrillation.
Study: NCT06430450

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements and saliva samples collection
Description: Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements and saliva samples collection
Description: Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements and saliva samples collection
Description: Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.
Study: NCT04829695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine drug combination
Description: Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
Study: NCT06543823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SupraTHEL 250
Description: the membrane is placed onto the wound bed and fixed in place by resorbable interrupted sutures

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Comparator
Description: no membrane is placed onto the wound bed , left bare to heal
Study: NCT05481060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screen-based simulation
Description: In the research, training will be given to the experiment group on intimate partner violence against women through screen-based simulation.
Study: NCT06330311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Evidence-based multimodal physiotherapy treatment based on learning and motor control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Evidence-based multimodal physiotherapy treatment based on learning and motor control
Study: NCT04366388

Intervention type: DEVICE
Intervention: ActivPAL3 VT (PAL Technologies Ltd).
Description: . The ActivPAL will be fitted by a trained research assistant on the mid-thigh of the participants' dominant leg. ActivPALs have an inclinometer that detects the joint angle of the thigh to capture lying, sitting, standing, and stepping activities.
Study: NCT06253468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
Study: NCT03908255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branch Chain Amino Acid
Description: Nutritional supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: Placebo
Study: NCT06526481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Transsphenoidal pituitary surgery : Double Nasoseptal Flap Technique
Description: Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~-On one side full sized nasoseptal flap will be elevated and a smaller sized nasoseptal flap will be elevated on the other side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Transsphenoidal pituitary surgery : Rescue Flap Technique
Description: Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~- A horizontal incision will be performed in the nasal septum in a posterior to anterior direction starting from the sphenoid ostium to a point opposite anterior end of the middle turbinate ( approximately up to one half of septum).
Study: NCT05008744

Intervention type: PROCEDURE
Intervention: Fetoscopic laser ablation
Description: Under ultrasound guidance, a 2 mm skin incision will be made and a 10Fr Cook Check Flow valve cannula and trocar will be introduced into the amniotic cavity.~The communicating vessels will be located endoscopically using a Storz straight or curved semirigid fetoscopes in a fetoscopic sheath, a Humanitarian Use Device, used with permission of the Federal Drug Administration under a Humanitarian Device Exemption agreement with Karl Storz, Inc, and will be ablated with a diode laser fiber that is passed through the operating channel of the endoscope.
Study: NCT06007001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Pilot 1a/b : the tele-rehabilitation intervention in BC or H\&N operated patients will consist of a series of exercises. The physiotherapist during teleconsultation rehabilitation program will explain to the patient how to perform the movements and regulate breathing. Practical advice on correct and incorrect habits will also be dispensed by the physiotherapist during the teleconsultation.~Pilot 2: the tele-rehabilitation intervention will consist of tele psychological support performed by a trained psychologist in each participating center It will consist of the learning of techniques for managing negative emotions, for relaxation and for implementing effective behavioural and coping strategies.~For each group, the TC will be scheduled every week for 8 weeks. The session will be available on a secure platform (Edumeet). Moreover, if they agree to, patients will also wear a smart watch to monitor physical parameters such as physical activity, sleeping and heart rate.
Study: NCT06278935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle-based intervention by an occupational therapist
Description: Participants with diabetic foot ulcers will be offered lifestyle-based treatment sessions virtually for up to 8 weeks with a licensed occupational therapist.
Study: NCT04332900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic hip strap
Description: The SERF Strap consist of a thin, elastic material that is secured to the proximal aspect of the leg, wraps in a spiral fashion around the thigh, and is anchored around the pelvis. The line of action of the SERF Strap pulls the hip into abdcution and external rotation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each that is made from a block of ethyl vinyl acetate with a thermo-moldable polymer (shore hardness of 45 A) and is manufactured through an automated computer numeric control machine (CNC routers).
Study: NCT06081842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contraceptive counseling strengthening intervention package
Description: Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraceptive counseling strengthening intervention package
Description: Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraceptive counseling strengthening intervention package
Description: Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.
Study: NCT05636696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Samen Minder Moe (Dutch intervention name)
Description: 'Samen Minder Moe' is a mindfulness-based cognitive behavioral therapy for cancer-related fatigue directed at couples.
Study: NCT06578546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 100mg d1, 200mg d2, 400mg d2-21, oral (Adjusted according to the plasma concentration of venetoclax on day 4)，every 28 days for a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2 qd, d1-d7, subcutaneous injection, every 28 days for a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orebatinib
Description: 20mg qod, d4-d21, oral, every 28 days for a treatment cycle.
Study: NCT04305327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Solution for subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brodalumab
Description: Solution for subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Solution for subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Solution for subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
Study: NCT06577311

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid hydrochloride 10% topical gel with Red Light
Description: Participants will have their facial Cutaneous Squamous Cell Carcinoma in situ (SCCis) prepped then treated with Aminolevulinic acid hydrochloride 10% topical gel (Ameluz ®), followed by red light therapy administered for 13 minutes and 30 seconds to deliver the total desired light dose to the SCCis lesion.
Study: NCT06578611

Intervention type: COMBINATION_PRODUCT
Intervention: Enhanced recovery after surgery
Description: Recommended pre-, intra-, and post-operative care interventions in the enhanced recovery after surgery.

Intervention type: COMBINATION_PRODUCT
Intervention: Enhanced recovery after surgery
Description: Recommended pre-, intra-, and post-operative care interventions in the enhanced recovery after surgery.
Study: NCT05098522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL201104
Description: lyophilised powder for reconstitution for IV dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for IRL201104
Study: NCT06430450

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements and saliva samples collection
Description: Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.